Khiron’s medical cannabis training gains UK CPD approval

The cannabis giant has earned CPD approval to bring its global education platform to UK doctors.

Medical cannabis company Khiron Life Sciences has secured UK Continuing Professional Development (CPD) accreditation for its global education platform, Khiron Academy.

UK healthcare professionals can now earn CPD credits completing the training, as Khiron’s goal to improve access to cannabis  through education continues. 

To date, nearly 1,000 medical professionals in Latin America and the UK have registered for, or completed the Khiron Academy training.

Over the last year, physicians trained by Khiron in Latin America have issued over 13,000 prescriptions, with a compound monthly growth rate of nearly 50 percent.

The training is available to members of the Medical Cannabis Clinicians Society (MCCS) and is a key element of the training of prescribers for Project Twenty21, the UK’s landmark 20,000-patient observational study led by Drug Science. 

Khiron has now partnered with Cellen, digital healthcare group and fellow founding member of Project Twenty21.

Khiron Academy will be made available to prescribers in the UK that have registered with Cellen’s education portal, MedCanHub.

Khiron Europe president, Tejinder Virk commented: “Over the last year, Khiron has seen a direct correlation between physician education and patient access. With Khiron Academy’s CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products.”

Eric Bystrom, CEO of Cellen added: “We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK. 

“Khiron is a clear global leader in medical cannabis education. We share common values in improving patient lives by educating doctors and optimizing the standard of medical care. Our aim is to create a practical guide for responsibly prescribing patients with safe and efficacious medical cannabis products.”